Bio-Rad Laboratories reported quarterly EPS of $1.89, well below the Zacks Consensus Estimate of $2.77 and down from $2.54 a year ago. The miss versus expectations and the year-over-year decline point to weaker near-term fundamentals. The report is likely to pressure the stock, though the article provides no revenue or guidance details.
Bio-Rad Laboratories reported quarterly EPS of $1.89, well below the Zacks Consensus Estimate of $2.77 and down from $2.54 a year ago. The miss versus expectations and the year-over-year decline point to weaker near-term fundamentals. The report is likely to pressure the stock, though the article provides no revenue or guidance details.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly negative
Sentiment Score
-0.46
Ticker Sentiment
